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Abstract
26S proteasome is a macromolecular multi-subunit complex responsible for recognizing, unfolding, and ultimately
destroying proteins. It remains poorly understood how 26S proteasome activity is regulated. The present study was to
investigate if AMP-activated protein kinase (AMPK) functions as a physiological suppressor of the 26S proteasome in
endothelial cells. 26S proteasome assembly, activity, and O-GlcNAcylation of P700 were assayed in cultured human
umbilical vein endothelial cells (HUVEC) and mouse aortas isolated from C57BL6 wild type and AMPKa2 knockout mice with
or without being exposed to selective AMPK activators or inhibitors. Pharmacological and genetic activation of AMPK
effectively suppresses 26S proteasomes in endothelial cells. Conversely, inactivation of AMPK either pharmacologically or
genetically increases 26S proteasome activity; furthermore, the inactivation decreases the O-GlcNAcylation of PA700/S10B
(the regulatory complex in 26S proteasomes) and increases the assembly of 26S proteasomes. In contrast, AMPK activation
increases levels of O-GlcNAcylated PA700/S10B, likely through enhanced association of PA700 with O-GlcNAc transferase
(OGT), the enzyme that catalyzes protein O-GlcNAcylation. Finally, aortas from AMPK-KO vs wild type mice exhibit elevated
26S proteasome activity in parallel with decreased PA700/S10B O-GlcNAcylation and PA700/S10B-OGT association. Taken
together, we conclude that AMPK functions as a physiological suppressor of 26S proteasomes.
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Introduction
The ubiquitin proteasome system (UPS) is the major non-
lysosomal degradative machinery for most intracellular proteins
[1,2]. A key component of this machinery is the 26S proteasome
[3], a macromolecular multi-subunit complex that is responsible
for recognizing, unfolding, and ultimately destroying proteins. To
be degraded, most target proteins must first be tagged with
polyubiquitin chains, generally at the e-NH2 group of an internal
lysine residue [4,5]. The 26S proteasome (a 2-MDa complex) is
made up of two sub-complexes: the catalytic particle (or 20S
proteasome) and the regulatory particle (19S proteasome) [3]. The
20S proteasome is a cylindrical protease complex consisting of 28
subunits configured into four stacks of heptameric rings. On the
other hand, the 19S (or PA700) consists of at least 18 subunits,
including 6 putative ATPases and 12 non-ATPase subunits [3,6].
The 26S proteasome is known to require ATP hydrolysis to
degrade ubiquitinated substrates and for its assembly [7]. Over the
past few years, it has become clear that deregulation of the UPS
leads to inappropriate destruction or accumulation of specific
proteins and ensuing pathological consequences [1]. The UPS is
now recognized as a regulator of the cell cycle and cell division
[8,9], immune responses and antigen presentation [10,11],
apoptosis [12], and cell signaling [13,14]. The UPS has been
shown to be either activated in certain cancers (e.g., multiple
myeloma) [15,16] or dysfunctional in neurodegenerative disorders
(e.g., Alzheimer’s disease, Huntington’s disease [17], and amyo-
trophic lateral sclerosis [18,19]).
AMPK was initially identified as a sensor of cellular energy
[20,21] and is also likely a sensor of cellular redox status [22,23].
As a phylogenetically conserved enzyme, AMPK is present in all
mammalian cells. AMPK is a heterotrimeric enzyme comprised of
a catalytic (a) subunit and two regulatory (b and c) subunits
[24,25]. AMPK is activated by at least three distinct signals: a
Ca
2+-dependent pathway mediated by calcium calmodulin-
dependent kinase kinase-b (CaMKK-b) [26], an AMP-dependent
pathway mediated by LKB1 [27], and TGF-b-activated kinase-1
(Tak1) [28] via phosphorylation at Thr172 on the a-subunit.
Binding of AMP to the c-subunit leads to allosteric activation of
AMPK, a change that also protects the Thr172 site from
dephosphorylation [29]. Once activated, AMPK switches on
catabolic pathways that generate ATP, while switching off ATP-
consuming processes (e.g., biosynthesis, cell growth, and prolifer-
ation). In this way, it functions as ‘‘energy gauge’’ [29,30]. This has
been regarded as a fundamental feature of multiple AMPK-
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normal conditions but is activated in response to hormonal signals
and stresses sufficient to increase the AMP/ATP ratio, such as
hypoglycemia, strenuous exercise, anoxia, and ischemia.
In contrast to traditional N- and O-glycosylation, which occurs
in secretory pathways (endoplasmic reticulum and Golgi) [31], O-
GlcNAcylation is defined as the O-linked attachment of N-
acetylglucosamine (O-GlcNAc) onto Ser/Thr residues of cytosolic
and nuclear proteins [32]. O-GlcNAcylation is an important
regulatory mechanism for signal transduction [32,33,34,35]. OGT
mediates O-GlcNAcylation, while removal of O-GlcNAc is
catalyzed by the complementary b-N-acetylhexosaminidase (O-
GlcNAcase, or OGlcNAc hydrolase as OGA). To date, more than
80 different proteins including transcription factors, kinases,
phosphatases, cytoskeletal proteins, nuclear hormone receptors,
nuclear pore proteins, signal transduction molecules, and actin
regulatory proteins [34,35] have been shown to undergo O-
GlcNAcylation [35] although the mechanisms underlying OGT
regulation are not completely understood.
Endothelial dysfunction, which is characterized by impaired
endothelium-dependent vasorelaxation [36,37,38], is a common
feature of CVD. During CVD, the endothelium losses its
homoeostatic potential to inhibit the disease process [38]. We
[39,40,41] and others [42] have shown that the UPS can
contribute to the development of endothelial dysfunction, which
is reflected as enhanced 26S proteasome activity, an accelerated
degradation of endothelial-protective molecules (such as the
guanosine 5-triphosphate cyclohydrolase I or GTPCH I, the rate
limiting enzyme essential for the de novo synthesis of an eNOS co-
factor [39,40,43]), and consequent impaired endothelium-depen-
dent vasorelaxation. Most importantly, we have discovered that
such an impairment can be restored by activation of AMPK [43].
Interestingly, we recently found that global knockout of both
AMPK and ApoE genes enhances NAD(P)H oxidase expression as
well as exacerbates atherosclerosis and endothelial dysfunction by
influencing 26S proteasome activation [44]. Further, we found
that AMPK activation alleviates diabetic endothelial dysfunction
by suppressing the 26S proteasome [43]. However, how AMPK
regulates 26S proteasome activity in these cases remains unknown.
Here we report that AMPK suppresses 26S proteasome activity by
promoting PA700/S10B-OGT association and PA700/S10B O-
GlcNAcylation.
Materials and Methods
Materials and animal model
Mouse-derived PA700/S10B antibody was from Abcam (Cam-
bridge, MA); MG132 from BioMol (Plymouth Meeting, PA);
fluorogenic proteasome substrates from Calbiochem (San Diego,
CA); Proteasome inhibitor MG132 was purchased from BioMol
(Plymouth Meeting, PA). 1% protease inhibitor cocktail were
obtained from Sigma (St Louis, MO). 1% phosphatase inhibitor
cocktail was purchased from Pierce. PUGNAc (O-GlcNAcase
inhibitor) was from Sigma (St Louis, MO). Anti-O-GlcNAc
antibody (CTD110.6 antibody, sc-59623) and negative control
siRNA or target-specific siRNA duplex against OGT were from
Santa Cruz Biotechnology (Santa Cruz, CA). Control siRNA
duplex and PA700-specific siRNA duplex were from Ambion
(Austin, TX). Protein-A Sepharose CL-4B was purchased from
Amersham Biosciences (Piscataway, NJ). All other chemicals were
obtained from Fisher Scientific (Pittsburgh, PA), unless otherwise
noted, were of the highest possible grade. Human umbilical vein
endothelial cells (HUVEC) were obtained from Cascade Biologics
(Walkersville, MD).
Control and AMPKa2
2/2 male mice were studied at 12 weeks
of age. The establishment and characterization of AMPKa2
2/2
mice were previously reported [45]. Animals were housed under
controlled temperature (21uC) and lighting, with 12 hours of light
and 12 hours of dark, and had free access to water and a standard
mouse chow diet. All procedures were approved by the University
of Oklahoma Health Sciences Center Institutional Animal Care
and Use Committee (IACUC Protocol: 10-005).
26S proteasome activity assay
26S proteasome function was assayed as described previously
but with minor modifications [46]. Chymotrypsin-like activity was
measured using SucLLVY-7-amido-4-methylcoumarin (AMC),
trypsin-like activity with Bz-VGR-AMC, and caspase-like activity
with Z-LLE-AMC. These fluorogenic proteasome substrates were
added to the cell lysate at a final concentration of 80 mMi n1 %
DMSO. ATP-dependent cleavage activity was monitored contin-
uously by detection of free 7-amido-4-methylcoumarin using a
fluorescence plate reader (Gemini, Molecular Devices) at 380/
460 nm at 37uC.
Adenoviral infection and siRNA transfection
Confluent HUVEC were infected with adenovirus encoding
AMPK-CA, AMPK-DN, or GFP (as adenoviral infection control),
as described previously [43]. SiRNA transfection was done, as
described previously [40].
Identification of O-GlcNAc-modified proteins in mouse
aortas
Aortas isolated from mice were weighed and homogenized in
lysis buffer containing 25 mmol/L HEPES (pH 7.0), 1 mmol/L
EDTA, 1 mmol/L EGTA, 1% NP-40, 0.1% SDS, 1% protease
inhibitor cocktail (Sigma, St Louis, MO), 1% phosphatase
inhibitor cocktail, and 1–100 mmol/L PUGNAc (O-GlcNAcase
inhibitor). Proteins modified by O-linked GlcNAc will be
immunoprecipitated with anti-O-GlcNAc antibody. Proteins were
released from the beads by boiling in Laemmli buffer containing
50 mmol/L dithiothreitol and separated by 12% SDS-PAGE.
Separated proteins were subjected to western blot analysis using
anti-PA700 antibodies.
Statistical analysis
Statistical comparisons of all results were analyzed using a one-
way ANOVA. Values are expressed as mean 6 SEM. p,0.05 is
considered as significant.
Results
AMPK inactivation increases 26S proteasome activity in
HUVEC
To determine whether AMPK inactivation alters proteasome
activity, we tested the effect of modulating AMPK activity on
proteasome activities in HUVEC. Compound C (0.5 mmol/L for
15 min), the nonselective inhibitor of AMPK [47], but not vehicle
(DMSO), significantly increased 26S proteasome activity, and this
effect could be reversed by co-incubation with MG132 (protea-
some inhibitor, 0.5 mmol/L) or AICAR (5-aminoimidazole-4-
carboxamide ribose, an AMPK activator) (Fig. 1A). As expected,
MG132 alone significantly inhibited proteasome activity (Fig. 1A).
However, AICAR alone for 6 h had no significant effect on 26S
proteasome activity (Fig. 1A), although prolonged incubation with
AICAR (overnight) did suppress 26S proteasome activity in
HUVEC [43].
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a similar effect as pharmacological AMPK inhibition by
compound C. Overexpression of an AMPK dominant negative
mutant (AMPK-DN), but not of GFP (control), also induced 26S
proteasome activation, while MG132 could block the activation
(Fig. 1B). Interestingly, unlike MG132, AICAR failed to inhibit
AMPK-DN promoted 26S proteasome activation (Fig. 1B),
suggesting that the suppressive effect of AICAR on proteasome
was mediated, at least in part, by AMPK activation. Together,
these results suggest that AMPK inactivation contributes to 26S
proteasome activation in HUVEC.
Of note, AMPK inactivation increased all 3 major protease-like
activities at various degrees (Fig. 1A and B). However, only
chymotrypsin-like activity could be significantly reversed or
suppressed by the treatment with AICAR (Fig. 1A) or MG132
(Fig. 1A and B) at indicated concentrations and duration of the
treatment. Therefore, we only used chymotrypsin-like activity to
demonstrate AMPK dependent effects on 26S proteasome activity
in subsequent cell experiments.
AMPK inhibition-induced 26S proteasome activation is
accompanied by increased 26S assembly
To confirm that AMPK responds to its activator or inhibitor as
reported, we first detected AMPK activation in challenged
HUVEC. As expected, AICAR promoted, but compound C
suppressed AMPK phosphorylation (Thr172), a marker of AMPK
activation, so as its downstream target ACC phosphorylation
(Ser79), based on quantified data that had been normalized with
the total AMPK or ACC protein levels (Fig. 2A). To begin to
understand how AMPK inactivation may activate the 26S
proteasome, we first determined if pharmacological or genetic
inactivation of AMPK affects 26S assembly (association), an event
known to be crucial for 26S proteasome activation [48,49,50].
Western blot analysis of PA700 immunoprecipitates using 20S
proteasome-specific antibody (against its b7 subunit) revealed that
a greater association occurred between PA700 and the 20S
proteasome in compound C-treated cells than in vehicle-treated
cells (Fig. 2B). However, co-incubation of cells with AICAR
abolished the effect of compound C. None of these treatments
altered either PA700 or b7 protein levels (Fig. 2B). To confirm the
26S proteasome assembly, we further separated the same samples
under non-reducing condition on a native gradient PAGE (3–
14%) and performed Western blot staining with antibodies to the
subunits of either 19S (PA700/S10B) or 20S proteasome sub-
complex (b7) on duplicate blots. As shown in Fig. 2C, on the same
molecular weight site (above the native protein marker 1236 kD)
of the duplicated blots, both staining for PA700/S10B and b7
were increased in the presence of compound C (Fig. 2C left), pre-
incubation with AICAR blocked the increase (Fig. 2C), suggesting
26S proteasome assembly enhancement did occur in the cells. The
enhanced 26S assembly was accompanied by an increase in 26S
proteasome activity (Fig. 2D).
Finally, given the potential non-selective effects of compound C
[47], we tested if AMPK-DN could replicate the effect of
compound C. HUVEC overexpressing AMPK-DN showed
enhanced 26S assembly compared to those overexpressing GFP
(control) or constitutively active AMPK (AMPK-CA) (Fig. 2E). Of
note, none of these treatments affected PA700 or the b7 protein
levels (Fig. 2E). Like in compound C-treated cells, the increased
26S proteasome assembly (association) in AMPK-DN overex-
pressing HUVEC was accompanied with an increase in 26S
proteasome activity (Fig. 1B), in contrasting to the suppressive
effect on 26S proteasome activity detected in AMPK-CA over-
expressing HUVEC [43]. The fact that 26S activation could
always be detected no matter how AMPK was inactivated suggests
that AMPK regulates 26S proteasomes.
AMPK activation increases OGT-PA700 association and
PA700 O-GlcNAcylation, while AMPK inactivation
decreases these outcomes
Next, we investigated whether modulation of AMPK activity
could alter the OGT-PA700 association and PA700 O-GlcNAcy-
lation. Western blot analysis of OGT immunoprecipitates using
specific PA700 antibody showed that compound C reduced OGT-
PA700 association, and this effect was reversed by AICAR
(Fig. 3A), consistent with the ability of compound C to decrease
PA700 O-GlcNAcylation in an AICAR-reversible manner
(Fig. 3A).
We also tested if genetic inhibition of AMPK through
overexpression of AMPK-DN produced a similar effect as
compound C. Compared to GFP overexpression, AMPK-DN
overexpression elicited a dramatic reduction in OGT-PA700
association (Fig. 3B), which might contribute to enhanced 26S
proteasome assembly (Fig. 2C) and activation (Fig. 2D). Impor-
tantly, although AICAR increased the association of inhibitory
OGT with PA700 in cells overexpressing GFP (Fig. 3B), this effect
was absent in cells overexpressing AMPK-DN (Fig. 3B), indicating
that AMPK participated in enhanced OGT-P700 association.
Conversely, constitutive activation of AMPK (overexpression of
AMPK-CA) resulted in greater OGT-PA700 association than
GFP overexpression (Fig. 3B). However, none of the treatments
altered the protein levels of PA700 or OGT (Fig. 3B).
Figure 1. AMPK suppression increases 26S activity in HUVEC.
AMPK suppression in HUVEC either by (A) compound C (10 mmol/L for
2 hour) or by (B) overexpression of AMPK-dominant negative mutant
(DN) increases 26S proteasome activities, as demonstrated by ATP-
dependent increased chymotrypsin-like, trypsin-like and caspase-like
activity on fluorescent proteasome substrates. MG132 (0.5 mmol/L for
1 hour) or AICAR (2 mmol/L for 6 hours) treatment blocks the increased
chymotrypsin-like activity in AMPK-suppressed HUVEC. * indicates
P,0.05 vs vehicle (DMSO) or GFP, n=3 per group.
doi:10.1371/journal.pone.0036717.g001
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To determine if OGT mediates AMPK suppression of
proteasome activity, we compared 26S proteasome assembly in
the presence of UDP-GlcNAc, a specific OGT substrate and
activator. Western blot analysis of PA700/S10B immunoprecip-
itates by using specific 20S proteasome antibody (to its b7 subunit)
revealed that activation of OGT by UDP-GlcNAc blocked
compound C-induced increases in 26S proteasome assembly
(Fig. 4A) and activation (Fig. 4B). OGT treatment also inhibited
the decrease of PA700/S10B O-GlcNAc modification (Fig. 4A).
Two dynamic enzymes directly control O-GlcNAcylation: OGT,
which catalyzes O-GlcNAcylation, and its negative regulator
OGA, which removes O-GlcNAc. Inhibition of OGA has been
shown to have synergistic effects on OGT activation [34]. We
investigated whether OGA, like OGT, participates in AMPK
regulation of the 26S proteasome. Surprisingly, inhibition of OGA
with PUGNAc did not prevent compound C-enhanced 26S
proteasome assembly, reduction of PA700/S10B O-GlcNAcyla-
tion (Fig. 4A) or activation (Fig. 4B). To confirm the functional
outcomes of altered 26S proteasome activity, we measured the
protein levels GTPCH I, which degradation is enhanced by 26S
proteasome activation [39,40,43]. As depicted in Fig. 4, 26S
proteasome activation by compound C reduced GTPCH I protein
levels (Fig. 4); pre-incubation of OGT activator UDP-GlcNAc, but
not OGA inhibitor PUGNAC, blocked the reduction of GTPCH I
(Fig. 4C). Collectively, these data indicate that OGT plays a major
role in AMPK regulation of the proteasome.
siRNA-mediated knockdown of OGT enhances 26S
proteasome assembly and activity
To determine whether OGT is required for 26S proteasome
regulation by AMPK, we performed knockdown experiments using
siRNA. We repeated the experiments previously shown in cells
infected with siRNA. As shown in Fig. 5, OGT protein levels were
more than 90% lower in cells transfected with OGT siRNA than in
control siRNA-treated cells. Surprisingly, knockdown of OGT
significantly increased 26S assembly, as reflected by an increase in
PA700 and b7 association (Fig. 5A), and 26S proteasome activity
(Fig. 5B). However, compound C did not further enhance 26S
proteasome assembly (Fig. 5A) and activity (Fig. 5B) in OGT
siRNA-transfected cells as it did in control siRNA cells (Fig. 5A and
B). The absence of this effect in OGT knockdown cells further
suggests that OGT is indispensable for AMPK regulation of the 26S
Figure 2. Increased 26S proteasome activity in AMPK-suppressed HUVEC is correlated with the enhanced association of 19S and
20S sub-complexes. Compound C (10 mmol/L for 2 hour)-treated HUVEC present (A) AMPK inactivation, (B) an increase in association of PA700/
S10B (from 19S complex) with b7 (from 20S complex), which can be blocked by AICAR pre-incubation (2 mmol/L for 6 hours), (C) 26S proteasome
assembly (same samples were run on 3–14% native-PAGE under non-reducing condition followed by conventional Western blot on duplicated blots
with PA700/S10B and b7 antibodies, respectively), and (D) an increase in 26S proteasome activity (chymotrypsin-like) (n=3). The increased
association of proteasome sub-complex is also observed in (E) HUVEC overexpressing AMPK-DN but not AMPK-CA or GFP. All of the blots shown are
representative of 3 independent experiments. NS represents not significant.
doi:10.1371/journal.pone.0036717.g002
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alter PA700 or b7 protein levels (Fig. 5A). Cumulatively, these
results suggest that, under basal conditions, AMPK serves to keep
the 26S proteasome at the minimal required activation level by
maintaining the association of OGT with PA700 and in turn,
keeping O-GlcNAcylation of PA700 in a constitutive state.
Figure 3. AMPK suppression is accompanied by the decreased association of OGT with proteasome. AMPK suppression in HUVEC either
by (A) compound C (10 mmol/L for 2 hour) or by (B) overexpression of AMPK-dominant negative mutant (DN) decreases both the OGT association
with proteasome and the O-GlcNAcylation of PA700/S10B (vs. controls), which can be reversed by AICAR pre-incubation (2 mmol/L for 6 hours) in
AMPK-present but not AMPK-DN cell. In contrast, constitutive activation of AMPK (overexpression of AMPK-CA vs GFP) (B) increases OGT-PA700
association. All of the blots shown are representative of 3 independent experiments. NS reprents not significant.
doi:10.1371/journal.pone.0036717.g003
Figure 4. Activation of OGT prevents AMPK-inhibition induced 26S proteasome activation. AMPK suppression by compound C (10 mmol/
L for 2 hour) in HUVEC (A) increases the association of PA700/S10B (from 19S complex) with b7 (from 20S complex) accompanied by a decrease of
PA700/S10B O-GlcNAc modification, and (B) increases 26S proteasome activity, which can be prevented by pre-incubation of UDP-GlcNAc (25 mmol/L
for 30 min), but not by PUGNAc (14 mmol/L for 30 min), the inhibitor of O-GlcNAcase. The blots shown are representative of 3 independent
experiments.
doi:10.1371/journal.pone.0036717.g004
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PA700/S10B association along with an increase in 20S
complex formation and 26S proteasome activity
We next explored if AMPK regulates the 26S proteasome in
vivo. We compared aortic proteins prepared from AMPKa2-KO
and WT (C57BL/6J) mice. Western blot analysis revealed that,
although AMPKa2 protein was undetectable in AMPKa2-KO
aortas (Fig. 6A), levels of b-actin (Fig. 6A), OGT (Fig. 6B), b7
(Fig. 6C) and PA700/S10B (Fig. 6) did not significantly differ
between WT and AMPK-KO aortas. However, compared to WT
aortas, AMPK-KO aortas exhibited a decrease in OGT-PA700/
S10B association (Fig. 6B), an increase in 26S assembly as seen by
an increase in PA700/S10B-b7 association (Fig. 6C), and an
increase in all three major protease-like activities of the 26S
proteasome (Fig. 6D).
Discussion
The present study has demonstrated that inactivation of AMPK
elevates 26S proteasome activity and that this effect is associated
with decreased PA700/S10B O-GlcNAcylation and increased 26S
proteasome assembly. Conversely, AMPK activation increases
GlcNAcylated PA700/S10B by stabilizing its association with
OGT, the key enzyme responsible for protein O-GlcNAcylation.
OGT appears to be crucial for this event, as AMPK-mediated 26S
proteasome inhibition is blocked by siRNA-mediated OGT
knockdown. The most conclusive evidence that AMPK suppresses
the 26S proteasome comes from analysis of aortas from AMPK-
knockout (AMPK-KO) mice. We found that, compared to wild
type (WT) aortas, aortas from AMPK-KO mice exhibit elevated
26S proteasome activity with decreased PA700/S10B O-GlcNA-
cylation and PA700/S10B-OGT association. Importantly, in spite
of different mechanisms underlying AMPK inactivation by
compound C and AMPK-DN, both treatments in HUVEC
induce 26S proteasome activation, indicating the essential role of
AMPK activity in 26S proteasome regulation. Furthermore, all the
promoted 26S proteasome activations through AMPK suppression
in HUVEC are attenuated by MG132, a potent proteasome
inhibitor, suggesting AMPK suppression is truly associated with
26S proteasome activation. Overall, our results support the notion
that AMPK, a sensor of cellular energy, maintains low basal 26S
proteasome activity by keeping PA700/S10B O-GlcNAcylated
and in turn, suppressing 26S proteasome activity and likely
preventing 26S proteasome-mediated degradation of endothelial
protective molecule(s).
In contrast to traditional N- and O-glycosylation, which occurs
in secretory pathways (endoplasmic reticulum and Golgi) [31], O-
GlcNAcylation is defined as the O-linked attachment of N-
acetylglucosamine (O-GlcNAc) onto Ser/Thr residues of cytosolic
and nuclear proteins [32]. O-GlcNAcylation is an important
regulatory mechanism for signal transduction [32,33,34,35]. OGT
mediates O-GlcNAcylation, while removal of O-GlcNAc is
catalyzed by the complementary b-N-acetylhexosaminidase (O-
GlcNAcase, or OGlcNAc hydrolase as OGA). To date, more than
80 different proteins including transcription factors, kinases,
phosphatases, cytoskeletal proteins, nuclear hormone receptors,
nuclear pore proteins, signal transduction molecules, and actin
regulatory proteins [34,35] have been shown to undergo O-
GlcNAcylation [35] although the mechanisms underlying OGT
regulation are not completely understood.
The most important finding of this paper is that we demonstrate
that OGT and its connection to the AMPK-mediated regulation
of 26S proteasome in endothelial cell. The present study
demonstrates that AMPK, as a physiological suppressor of 26S
proteasome, regulates proteasome function by controlling OGT-
mediated proteasome O-GlcNAcylation. Indeed, there is evidence
that 19S subunit can be subjected to O-GlcNAcylation with
consequent 26S proteasome inhibition [51]. Hence, O-GlcNAc is
considered an endogenous inhibitor of the 26S proteasome [51]. A
proteomic study revealed that several other proteins in the 26S
proteasome can also be extensively O-GlcNAcylated [52]. Hence,
O-GlcNAc is considered an endogenous inhibitor of the 26S
proteasome [51] and O-GlcNAc modification links a nutritional
sensor to modulation of proteasome function [53]. Intriguingly,
AMPK, a cellular energy sensor and a major component of the
nutrient pathway [54], has recently been linked to O-GlcNAc
Figure 5. Loss of OGT increases 26S proteasome assembly. HUVEC transfected with OGT siRNA but not control siRNA show an increase in (A)
association of PA700/S10B (from 19S complex) with b7 (from 20S complex) and (B) 26S proteasome activity, mimicking the effect of AMPK-
suppression by compound C (10 mmol/L for 2 hour). The blots shown are representative of 3 independent experiments. * represents p,0.05 vs the
control (without compound C treatment).
doi:10.1371/journal.pone.0036717.g005
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independent of a direct association between OGT and AMPK
[56], though co-immunoprecipitation of these proteins is possible
[57]. In line with this relationship, we found that OGT is essential
in mediating AMPK-dependent 26S proteasome suppression both
in cultured cells and aortas of AMPK2a-KO mice, likely through
the control of PA700/S10B modification. These data suggest that
a novel functional link exists between AMPK and OGT that
regulates 26S proteasome function in endothelial cell.
It is worthy of note that compared to the effect of AMPK-DN,
AMPK-CA alone did not generate a robust changes in 26S
proteasomes assembly. This is in line with the observations that
AMPK-CA alone has either marginal [43,44] or not significant
effects on 26S proteasome activity. All these data might imply that
basal AMPK activity is essential in keeping 26S proteasome
activity in check; further studies are warranted.
The concept that AMPK activation could be used as a strategy
to promote vascular health, including overcoming endothelial
dysfunction, has only recently emerged [22,58,59]. Endothelial
dysfunction, characterized by impaired endothelium-dependent
vasorelaxation, is a common feature of CVD including diabetes
and hypertension. We have recently shown that link exists between
26S proteasome activation and endothelial dysfunction through
accelerated proteasomal degradation of GTP-CH I and conse-
quent BH4 deficiency [39,40]. More importantly, we have
demonstrated that activation of AMPK by Metformin reverses
endothelial dysfunction in a 26S proteasome-dependent fashion in
streptozotocin-induced diabetic mice [43]. Thus, our data suggest
that AMPK-dependent OGT-mediated 26S proteasome suppres-
sion might operate in vivo contributing to the protective effect of
AMPK on endothelial function in our previous studies [43,44] In
summary, this is the first report of a novel function for AMPK-
dependent 26S proteasome regulation in endothelial cells, a
mechanism that may bridge endothelial function with both the
energy (AMPK) and metabolic (OGT) sensors.
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